Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | Trastuzumab deruxtecan in metastatic HER2+ breast cancer

Sibylle Loibl • 6 Dec 2022
SABCS 2022
Breast Cancer Antibodies Capecitabine Lapatinib Trastuzumab deruxtecan Trastuzumab emtansine
DESTINY-Breast02

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses the successes of trastuzumab deruxtecan for breast cancer in the HER2-positive metastatic breast cancer setting, such as seen in the Phase III DESTINY-Breast02 (NCT03523585) trial which demonstrated significant delays in disease progression. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sibylle Loibl

1:28
Long-term survival of the Phase II GeparOLA study
Sibylle Loibl • 6 Dec 2022
0:36
Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer
Sibylle Loibl • 6 Dec 2022
1:43
Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancer
Sibylle Loibl • 6 Dec 2022
1:03
Key takeaways from SABCS 2022
Sibylle Loibl • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals